axon-degeneration
(3)
Scott Greenberg
Scott Greenberg is the Chief Business Officer of Nura Bio, a clinical-stage biopharmaceutical company in South San Francisco building small-molecule drugs to stop nerves from dying. He joined in February 2025 to steer business development and corporate strategy as the company pushes its lead SARM1 inhibitor, NB-4746, into the clinic. He arrives with more than two decades crossing the line between finance and biology - a Goldman Sachs banking start, more than a decade at Celgene, an operations leadership role at Roivant Sciences, and a stint as Chief Operating Officer at Aro Biotherapeutics. He studied both Finance and the Biological Basis of Behavior at the University of Pennsylvania before an MBA at Harvard.
Nura Bio
Nura Bio is a clinical-stage biopharmaceutical company in South San Francisco developing brain-penetrant, small-molecule neuroprotective medicines. Its work centers on SARM1, an injury-activated NAD hydrolase that triggers axon degeneration, an early and common event across many neurological diseases. The lead candidate, NB-4746, is an oral, brain-penetrant SARM1 inhibitor that completed Phase 1 in healthy volunteers and shows protection in preclinical models of ALS, MS, traumatic brain injury and chemotherapy-induced peripheral neuropathy. The company has raised more than $140 million in Series A financing led by The Column Group.
Shilpa Sambashivan
Shilpa Sambashivan is the CEO and a co-founder of Nura Bio, a South San Francisco biotech building brain-penetrant small molecules that aim to stop nerves from dying. A protein biochemist by training, she helped spin the company out of academic labs in 2018, built its R&D engine as Chief Scientific Officer, and was elevated to CEO in September 2024 alongside a $68M Series A extension that pushed total funding past $140M. Her lead drug, NB-4746, blocks the SARM1 enzyme that triggers axon self-destruction.